NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
June 13, 2006 • Volume 3 / Number 24 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Article

Molecular Profiling Can Accurately Diagnose Burkitt's Lymphoma

Researchers have identified genetic signatures for distinguishing between two types of lymphomas: Burkitt's and diffuse large-B-cell (DLBCL). This distinction is critical because patients with Burkitt's lymphoma require more intense chemotherapy than those with DLBCL. Burkitt's lymphoma is fatal if untreated, and accurate diagnosis will have a major effect on these patients' prognosis.

Burkitt's lymphoma and DLBCL cells look similar under the microscope, and diagnosis can be difficult using conventional pathological methods. A study in the June 8 New England Journal of Medicine describes how gene-expression microarray technology can improve diagnosis of Burkitt's lymphoma.

The study resulted from the collaboration between NCI investigators and the multinational team of researchers in the Lymphoma/Leukemia Molecular Profiling Project. A panel of expert hematopathologists began by reevaluating samples that had been previously diagnosed as Burkitt's lymphoma or atypical Burkitt's lymphoma using available pathological methods. They reclassified a number of samples (originally diagnosed as Burkitt's lymphoma) as DLBCL or high-grade lymphomas, thus demonstrating the difficulty in making an accurate diagnosis.  Read more  

Director's Update

Taking Pride in an Important Achievement

An important public health milestone was reached last week when FDA approved a vaccine that prevents infection by the two types of the human papillomavirus (HPV) responsible for up to 70 percent of cervical cancer cases worldwide, HPV 16 and HPV 18, as well as two other HPV types, HPV 6 and HPV 11, that cause benign genital warts.

Our nation's strong commitment and investment in cancer research at NCI led to this approval, something in which we all can take great pride. NCI investigators throughout the institute were involved in the discovery that HPV causes cervical cancer. Most prominent among NCI scientists working on this project were Drs. Douglas Lowy and John Schiller of the Center for Cancer Research (CCR). They also were instrumental in the discovery of the virus-like particle technology that led to the vaccine's development.

Called Gardasil and manufactured by Merck & Co., this vaccine will provide a significant boost to NCI's efforts to reduce the burden of disease by eliminating the need for invasive procedures to remove many precancerous lesions. But its impact will likely be greatest in developing countries where a lack of public health infrastructure and screening programs results in hundreds of thousands of lives lost each year to cervical cancer.  Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit

NCI Cancer Bulletin staff can be reached at